Table 1 Baseline characteristics and pathological outcomes of patients. BMI - body mass index; ASA - American Society of Anesthesiologists; CA19-9 - carbohydrate antigen 19 − 9; SCA - serous cystic adenoma; MCN - mucinous cystic neoplasm; SPN - solid pseudopapillary tumor; IPMN - intraductal papillary mucinous neoplasm; PNET - pancreatic neuroendocrine neoplasm
Parameter | LDPPHR group | LPD group | P value |
|---|---|---|---|
(n = 31) | (n = 29) | ||
Age (years) | 48.4 ± 15.8 | 52.3 ± 11.9 | 0.29 |
Gender (n, %) | |||
male | 8 (25.8%) | 14 (48.3%) | 0.07 |
female | 23 (74.2%) | 15 (51.7%) | |
Preoperative comorbidities (n, %) | |||
hypertension | 7 (22.6%) | 4 (13.8%) | 0.51 |
diabetes | 3 (9.7%) | 2(6.9%) | 1.00 |
anemia | 2 (6.5%) | 0 | 0.49 |
Bronchial Asthma | 1 (3.2%) | 0 | 1.00 |
Abdominal surgery history (n, %) | 4(12.9%) | 6(20.7%) | 1.00 |
BMI (kg/m2) | 24.9 ± 4.0 | 23.9 ± 2.9 | 0.26 |
ASA (n, %) | |||
I | 16 (51.6%) | 19 (65.5%) | 0.64 |
II | 14 (45.2%) | 9 (31.0%) | |
III | 1 (3.2%) | 1 (3.4%) | |
Preoperative hemoglobin (g/L) | 127.6 ± 18.2 | 133.7 ± 16.3 | 0.18 |
Preoperative total bilirubin (mmol/L) | 11.4 (8.1,12.9) | 12.4 (10.1,16.5) | 0.06 |
Preoperative direct bilirubin (mmol/L) | 2.1 (1.5,2.7) | 2.3 (1.8,3.1) | 0.10 |
Preoperative albumin (g/L) | 40.1 ± 2.9 | 40.8 ± 4.1 | 0.41 |
Preoperative CA19-9 (IU/mL) | 9.7 (7.1,13.4) | 11.1 (6.0,16.5) | 0.89 |
Pathological diagnosis | |||
SCA | 9 (29.0%) | 4(13.8%) | 0.16 |
MCN | 1(3.2%) | 6(20.7%) | |
SPN | 7(22.6%) | 8(27.6%) | |
IPMN | 8(25.8%) | 8(27.6%) | |
PENT(G1/G2) | 5(16.1%) | 2(6.9%) | |
Vesicular transformation | 1(3.2%) | 0 | |
Benign cystic lesions | 0 | 1(3.4%) | |
Lesion diameter (cm) | 2.8 (1.6,5.0) | 3.5 (2.5,4.7) | 0.32 |